ASCO Annual Meeting 2022: Neue Daten zu Antikörper-Drug-Konjugaten (ADCs) und CDK4/6-Inhibitoren beim metastasierten Mammakarzinom

Oncology Research and Treatment

Conference Report

Free Access

Emrich G.
Abstract

In der DESTINY-Breast04-Studie zeigte das ADC Trastuzumab-Deruxtecan bei vorbehandelten Patientinnen mit niedriger HER2-Expression eine deutliche Verlängerung des progressionsfreien Überlebens (PFS) sowie des Gesamtüberlebens (OS) verglichen mit konventioneller Chemotherapie nach Wahl des Behandlers [1]. Positive Ergebnisse gab es auch aus der TROPiCS-02-Studie mit dem ADC Sacituzumab-Govitecan bei Patientinnen mit metastasiertem, hormonresistentem Mammakarzinom [2]. Interessant waren auch die Ergebnisse der MAINTAIN-Studie zur Frage, ob CDK4/6-Inhibitoren bei Patientinnen mit HR+/HER2-negativem metastasiertem Mammakarzinom nach Fortschreiten der Erkrankung weiter verabreicht werden sollten [3]

S. Karger AG, Basel

Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif